ClinicalTrials.gg
TerminatedNCT05734196ENERGYUpdated Oct 15, 2026

The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency

A Phase 1 interventional study of INZ-701 in Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets and Generalized Arterial Calcification of Infancy, sponsored by Inozyme Pharma. Terminated at 5 sites in 3 countries. Open to participants aged Up to 1 Year. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Inozyme Pharma (part of BioMarin Pharmaceutical) · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated by the sponsor prior to planned completion based on a review of the data across indications and overall program considerations. Study termination was not related to participant safety.
Updated Oct 15, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
Up to 1 Year
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Pseudoxanthoma Elasticum with a site in United States — none open to participants now, none under way, none of them phase 3. Pseudoxanthoma Elasticum · United States.

Started
2023
the only one that year
Phase 1
Only one
of the 10
Registered
9th of 10
by date
Lead sponsor
4 of 10
Inozyme Pharma

Among the 10 studies in Pseudoxanthoma Elasticum with a site in United States, this one is the only one that started in 2023, is the only one in phase 1, and was the 9th registered.

Pseudoxanthoma Elasticum

32 studies on the registry are indexed under Pseudoxanthoma Elasticum; 6 are open to participants now.

Browse Pseudoxanthoma Elasticum studies →

Open to participants now

None of the 10 studies in Pseudoxanthoma Elasticum with a site in United States is open now. The open studies under Pseudoxanthoma Elasticum, anywhere →

Who these studies take

Of the 6 Pseudoxanthoma Elasticum studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: Up to 1 Year · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Pseudoxanthoma Elasticum with a site in United States as a file.
02

Study summary

The primary purpose of Study INZ701-104 (the ENERGY study) is to assess the safety and tolerability of INZ-701 in infants with ENPP1 Deficiency or with ABCC6 Deficiency.

Read the detailed description

INZ-701 is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzyme replacement therapy in development for the treatment of the ultra-rare genetic disorder, ENPP1 Deficiency or with ABCC6 Deficiency.

Study INZ701-104 (the ENERGY study) is a Phase 1b, open-label study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of INZ-701 in infant study participants with ENPP1 Deficiency or ABCC6 Deficiency.

The study will consist of up to a 60-day Screening Period, a 52-week Treatment Period during which study participants will receive INZ-701, an Extension Period during which participants may continue to receive INZ-701 until it is commercially available in the country where the participant resides, or until an alternative study of INZ-701 is available, and an End of Treatment (EOT) visit 30 days after the last dose of INZ-701. Upon treatment discontinuation, participants will continue to be followed for their ongoing disposition for survival outcome at least quarterly through the end of the study.

03

Conditions studied

  • Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
  • Autosomal Recessive Hypophosphatemic Rickets
  • Generalized Arterial Calcification of Infancy
  • ATP-Binding Cassette Subfamily C Member 6 Deficiency
  • Pseudoxanthoma Elasticum

Keywords

  • ectonucleotide pyrophosphatase/phosphodiesterase1 deficiency
  • hypopyrophosphatemia
  • ENPP1
  • Generalized Arterial Calcification of Infancy
  • GACI
  • Autosomal Recessive Hypophosphatemic Rickets Type 2
  • ARHR2
  • ATP-Binding Cassette Subfamily C Member 6 Deficiency
  • ABCC6
  • Pseudoxanthoma elasticum
  • PXE
04

Who can participate

Ages eligible
Up to 1 Year
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Infant aged ≤ 1 year at the time of enrollment
  2. Study participant must have a confirmed post-natal molecular genetic diagnosis of ENPP1 Deficiency or ABCC6 Deficiency
  3. Study participants must have clinical manifestations of generalized arterial calcification of infancy (GACI) or GACI-2, which must include at least one of the following: ectopic calcification, heart failure, respiratory distress, edema, cyanosis, hypertension, and cardiomegaly.
  4. Study participant must weigh ≥0.5 kg at the time of the first dose of INZ-701 in this study
  5. Written provided by a parent or legal guardian

Exclusion criteria

Exclusion Criteria:

  1. In the opinion of the Investigator, presence of any disease or laboratory abnormality that precludes study participation or may confound interpretation of study result
  2. Receiving end of life or hospice care
  3. Known
  4. Concurrent participation in another non-Inozyme interventional study
  5. Treatment with any non-Inozyme product or device during study participation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    INZ-701

    The first 2 study participants will receive 1 dose of 0.2 mg/kg on Day 1 and start at Dose Level A (0.2 mg/kg twice weekly) on Day 8. The Data Review Committee (DRC) comprised of representatives of the Sponsor, the study Investigators, and a physician who is a subject matter expert not affiliated with the study or Sponsor, will review the safety data of the first study participant through Day 8. Contingent upon this review, the Sponsor will decide if additional study participants can begin receiving INZ-701. After the second study participant completes Day 32, the DRC will perform a cumulative review of safety and PK/PD data and will make dosing recommendations, for example, modifying the dose of the ongoing study participants and/or changing the starting dose for future participants. Dose Level A: 0.2 mg/kg twice weekly Dose Level B: 0.6 mg/kg twice weekly Dose Level C: 0.2 mg/kg once weekly Dose Level D: 0.6 mg/kg once weekly Dose Level E: 1.8 mg/kg once weekly

    Drug: INZ-701

Interventions

  • Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.

    Also known as: (rhENPP1-Fc).

06

What researchers measure

Primary outcomes

  1. Number of Treatment Emergent Adverse Events (TEAEs)

    Treatment-emergent AEs are defined as any AE occurring from the first dose of INZ-701 through 30 days after the last dose of INZ-701.

    Time frame: 52 weeks (Treatment Period)

  2. Incidence of Anti-Drug Antibodies (ADA)

    For each participant, the presence of ADAs will be assessed and, if present, further evaluation will determine specificity and subtypes.

    Time frame: 52 weeks (Treatment Period)

  3. Left Ventricular Ejection Fraction

    For each participant, an echocardiogram will be collected, and used to assess heart function. (Including measurement of left ventricular ejection fraction), and to identify any other abnormalities, for example, calcification of heart valves.

    Time frame: 52 weeks (Treatment Period)

Secondary outcomes

  1. Change from Baseline in Plasma Inorganic Pyrophosphate (PPi) Levels

    For each participant, plasma PPi will be measured via a series of blood samples obtained throughout the study, comparing the participant's baseline value over time.

    Time frame: 52 weeks (Treatment Period)

  2. Area under the Plasma Concentration versus Time Curve (AUC) of INZ-701

    For each participant, variation of concentration of INZ-701 in the plasma will be measured via a series of blood samples obtained throughout the study, comparing the participant's baseline value over time.

    Time frame: 52 weeks (Treatment Period)

  3. Maximum Plasma Concentration (Cmax) of INZ-701

    For each participant, the maximum concentration of INZ-701 in the plasma will be measured via a series of blood samples obtained throughout the study, comparing the participant's baseline value over time.

    Time frame: 52 weeks (Treatment Period)

  4. ENPP1 Activity

    For each participant, the activity of INZ-701 in the serum will be measured via a series of blood samples obtained throughout the study, comparing the participant's baseline value over time.

    Time frame: 52 weeks (Treatment Period)

07

Study locations

5 sites
  • Rady Children's Hospital
    San Diego, California 92123, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Hospital Sant Joan de Déu
    Barcelona, Spain
  • Royal Manchester Children's Hospital
    Manchester, M13 9WL, United Kingdom
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2023 to primary completion in Sep 2026, 39 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Oct 2026 → Sep 2026 and completion Oct 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2023
First posted
Feb 17, 2023
StartActual
Jun 25, 2023
Primary completionActual
Sep 29, 2026was Oct 2026
CompletionActual
Sep 29, 2026was Oct 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated The study was terminated by the sponsor prior to planned completion based on a review of the data across indications and overall program considerations. Study termination was not related to participant safety.
changed Oct 15, 2026
Primary completion
Oct 14, 2026→Sep 29, 2026 (actual)
Oct 15, 2026
Study completion
Oct 14, 2026→Sep 29, 2026 (actual)
Oct 15, 2026
Enrollment
16 (estimated)→9 (actual)
Oct 15, 2026
Show all 2 updates
  1. Oct 15, 2026
    Active, not recruiting→Terminated
    Why stopped The study was terminated by the sponsor prior to planned completion based on a review of the data across indications and overall program considerations. Study termination was not related to participant safety.
    Primary completion Oct 14, 2026→Sep 29, 2026 (now actual)
    Study completion Oct 14, 2026→Sep 29, 2026 (now actual)
    Enrollment 16 (estimated)→9 (actual)
    + 1 other change: verification date
  2. Sep 29, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05734196
Lead sponsor
Inozyme Pharma
Responsible party
Sponsor
First posted
Feb 17, 2023
Start date
Jun 25, 2023
Primary completion
Sep 29, 2026
Completion
Sep 29, 2026
Last update
Oct 15, 2026

Study contacts

Medical Director, MD, MD
study director · BioMarin Pharmaceutical

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efmirenpase alfa

Start the discussion